anti-inflammatoty and immuno-therapy - versus placebo - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.42 [0.38, 5.28]< 10%5 studies (5/-)30.2 %lownot evaluable highcrucial-
deaths 0.59 [0.29, 1.22]< 10%10 studies (10/-)92.3 %lowlow highcrucial-
hospitalization or death 0.42 [0.26, 0.68]< 172%8 studies (8/-)100.0 %some concernserious moderatecrucial-
clinical deterioration 0.24 [0.10, 0.56]< 10%1 study (1/-)100.0 %NAnot evaluable important-
clinical improvement (14-day) 1.19 [0.78, 1.81]> 10%1 study (1/-)79.1 %NAnot evaluable important-
clinical improvement (28-day) 1.28 [0.84, 1.96]> 10%1 study (1/-)87.2 %NAnot evaluable important-
clinical improvement (7-day) 0.92 [0.51, 1.66]> 10%1 study (1/-)39.1 %NAnot evaluable important-
hospitalization 0.73 [0.51, 1.06]< 165%7 studies (7/-)95.2 %lownot evaluable highimportant-
mechanical ventilation 0.63 [0.29, 1.37]< 19%2 studies (2/-)87.6 %lownot evaluable highimportant-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %NAnot evaluable important-
viral clearance 1.08 [0.45, 2.60]> 172%2 studies (2/-)56.6 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.45 [0.70, 2.99]> 144%3 studies (3/-)84.4 %some concernnot evaluable moderateimportant-
recovery 1.25 [0.71, 2.22]> 10%1 study (1/-)78.2 %NAnot evaluable non important-

safety endpoints 00

emergent treatment-resistant variants 0.64 [0.08, 4.94]< 167%2 studies (2/-)66.3 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.74 [1.50, 2.03]< 10%1 study (1/-)0.0 %NAnot evaluable important-
serious adverse events 0.75 [0.54, 1.05]< 12%2 studies (2/-)95.1 %lownot evaluable highimportant-
adverse events 0.76 [0.54, 1.06]< 143%3 studies (3/-)94.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.